Who is sponsoring NCT06744829?

NCT06744829 is sponsored by Mikromic Medical, S. L.

What drugs are being tested in NCT06744829?

Interventions in NCT06744829: Balloon placement and inflation and removal of the Balloon.

What condition does NCT06744829 study?

NCT06744829 studies Overweight/Obesity.

Is NCT06744829 still recruiting?

NCT06744829 is currently completed. Last updated 20 December 2024.

Last reviewed 2024-12-20 · How we verify

NCT06744829

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

STELLA® Endogastric Balloon System. Evaluation of Safety and Introduction System at 7 Months.

Completed NA Last updated 20 December 2024

What this trial tests

NA trial testing Balloon placement and inflation and removal of the Balloon in Overweight/Obesity in 69 participants. Completed in 5 December 2023.

Timeline

1 April 2022

Primary endpoint
5 December 2023

5 December 2023

Quick facts

Lead sponsor	Mikromic Medical, S. L
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	69
Start date	1 April 2022
Primary completion	5 December 2023
Estimated completion	5 December 2023
Sites	1 location across Spain

Drugs / interventions tested

Balloon placement and inflation and removal of the Balloon

Conditions studied

Overweight/Obesity — all drugs for Overweight/Obesity →

Sponsor

Mikromic Medical, S. L

Who can join

Adults 18 to 65, any sex, with Overweight/Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of the study was to evaluate the safety of the introduction of STELLA® endogastric balloon and the endogastric balloon itself at 7 months. This investigation included screening visits and studies prior to placement, the endoscopic act of placement, the entire follow-up period while the balloon remains inside the stomach (6 months), the endoscopic act of balloon removal, as well as an additional follow-up after balloon removal of 1 month (7 months in total). Clinical, analytical and endoscopic parameters have also been evaluated.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prospective, Multicenter Clinical Trial to Evaluate the Safety of the Stella® Intragastric Balloon at 7 Months and the Balloon Delivery System.
Espinet-Coll E, Turró-Arau R, Nebreda-Durán J, Abad-Belando R, et al · · 2025 · PMID 40968297 · DOI 10.1007/s11695-025-08264-y

Verify or expand the search:

Other recruiting trials for Overweight/Obesity

Currently open trials in the same condition.

NCT07428187 — Snacking Effects on the Brain Response to Foods and Satiety During Dieting · NA · recruiting
NCT07505745 — MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity · Phase 2 · recruiting
NCT07382908 — Bioequivalence Study of BGM0504 Injection · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06744829 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mikromic Medical, S. L
Last refreshed: 20 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06744829.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing